(Washington) The Federal Drug Enforcement Administration (FDA) in the United States is expected to approve Pfizer’s Govt-19 vaccine for 12 and more young people within the next week, a federal official said. This will allow them to be vaccinated before the start of the next school year.
The announcement is expected to come a month after the manufacturer found that its vaccine, which is already licensed for 16-year-olds and older, provides protection for the younger generation.
Notice within the next week
Speaking anonymously to discuss the FDA’s action, the federal official said that the emergency application for Pfizer’s two-dose vaccine should be extended early next week and may be earlier.
Another person familiar with the matter spoke anonymously to discuss internal matters, confirmed the upcoming announcement, and expects the FDA to approve the use of Pfizer even for younger children this fall.
The FDA’s move follows a meeting of the Federal Vaccine Advisory Council to discuss the possibility of prescribing the vaccine to children between the ages of 12 and 15. Medications may begin to be dispensed after being approved by the Centers for Disease Control and the group’s recommendation. These steps can be completed in a few days.
No cases were reported between 12 and 15 years of age
At the end of March, there were 2,260 U.S. people aged 12 to 15. Pfizer released preliminary results from a volunteer vaccination study that showed no cases of COVID-19 among adolescents who received the full vaccine, compared with 18 of those who received the Sham injection.
The company says teenagers have the same side effects as teenagers. The main side effects are pain, fever, chills and fatigue, especially after the second dose. This study will follow participants for two years for additional information on long-term safety and security.
Pfizer is not the only company that wants to lower the age limit for its vaccine. Results from the U.S. study of the Moderna vaccine for young people between the ages of 12 and 17 are expected in the middle of this year.